<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842865</url>
  </required_header>
  <id_info>
    <org_study_id>CL-PTL-132</org_study_id>
    <nct_id>NCT03842865</nct_id>
  </id_info>
  <brief_title>Expanded Access of Vigil in Solid Tumors</brief_title>
  <official_title>An Expanded Access Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gradalis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gradalis, Inc.</source>
  <brief_summary>
    <textblock>
      This is a multicenter, expanded access protocol of intradermal autologous Vigil&#xD;
      immunotherapy. Subjects meeting expanded access eligibility criteria will receive a minimum&#xD;
      of 1 immunotherapy dose of Vigil (1 x 10e4, 1 x 10e5, or 1 x 10e6 cells/injection),&#xD;
      intradermally every 4 weeks as monotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 40 subjects who had tissue procured and Vigil manufactured but fail&#xD;
      manufacturing release criteria under a previous Gradalis protocol are considered for this&#xD;
      study.&#xD;
&#xD;
      Participants will be managed in an outpatient setting. Hematologic function, liver enzymes,&#xD;
      renal function and electrolytes will be monitored. Blood for immune function analyses in&#xD;
      response to autologous tumor antigens will be collected at screening, Day 1 (prior to Vigil&#xD;
      administration) at Cycles 2, 4, and 6, end of treatment (EOT); 3 months after EOT, and every&#xD;
      6 months thereafter for those in response follow up. For subjects with Ewing's sarcoma, blood&#xD;
      for ctDNA analysis will be collected at screening, on Day 1 prior to Vigil administration at&#xD;
      Cycles 2, 3, 4, and 6, and EOT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Temporarily not available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Solid Tumor</condition>
  <condition>Ewing Sarcoma</condition>
  <condition>Ewing's Tumor Metastatic</condition>
  <condition>Ewing's Sarcoma Metastatic</condition>
  <condition>Advanced Gynecological Cancers</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Uterine Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vigil</intervention_name>
    <description>Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms (TGFβ-1 and TGFβ-2).</description>
    <other_name>Engineered Autologous Tumor Cell Immunotherapy</other_name>
    <other_name>FANG</other_name>
    <other_name>IND 14205</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Study Enrollment Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed advanced or metastatic non-curable solid tumor.&#xD;
&#xD;
          2. Completed manufacture of at least 1 vial of Vigil, but failure of one or more&#xD;
             manufacturing release criteria.&#xD;
&#xD;
          3. ECOG performance status (PS) 0-1 or Karnofsky performance status (KPS) / Lansky&#xD;
             performance status (LS)≥ 70%.&#xD;
&#xD;
          4. Normal organ and marrow function as defined below:&#xD;
&#xD;
             Absolute granulocyte count ≥1,000/mm3, Absolute lymphocyte count ≥400/mm3, Platelets&#xD;
             ≥75,000/mm3, Hemoglobin ≥ 8.0 mg/dL, Total bilirubin ≤ institutional upper limit of&#xD;
             normal*, AST(SGOT)/ALT(SGPT) ≤2x institutional upper limit of normal, Creatinine &lt;1.5&#xD;
             mg/dL&#xD;
&#xD;
             *documented Gilbert's syndrome may be considered after medical monitor review&#xD;
&#xD;
          5. No systemic therapy, immunologic therapy or investigational therapy within 2 weeks and&#xD;
             no radiation therapy within 1 week prior to enrollment.&#xD;
&#xD;
          6. Subject has recovered to CTCAE Grade 1 (except for parameters noted in Item 4, above)&#xD;
             or better from all adverse events associated with prior therapy or surgery.&#xD;
             Pre-existing motor, sensory neurologic pathology or symptoms, or dermatologic&#xD;
             toxicities must be recovered to CTCAE Grade 2 or better.&#xD;
&#xD;
          7. If female of childbearing potential, has a negative urine or serum pregnancy test. If&#xD;
             the urine test is positive or cannot be confirmed as negative, a negative serum test&#xD;
             will be required for study entry.&#xD;
&#xD;
          8. Ability to understand and the willingness to sign a written informed protocol specific&#xD;
             consent or a parental/guardian informed consent and pediatric assent when appropriate.&#xD;
&#xD;
        Study Enrollment Exclusion Criteria:&#xD;
&#xD;
          1. Medical condition requiring any form of chronic systemic immunosuppressive therapy&#xD;
             (steroid or other) except physiologic replacement doses of hydrocortisone or&#xD;
             equivalent (no more than 30 mg hydrocortisone or 10 mg prednisone equivalent daily)&#xD;
             for &lt; 30 days duration.&#xD;
&#xD;
          2. Known history of other malignancy unless having undergone curative intent therapy&#xD;
             without evidence of that disease for ≥ 3 years except cutaneous squamous cell and&#xD;
             basal cell skin cancer, superficial bladder cancer, in situ cervical cancer or other&#xD;
             in situ cancers are allowed if definitively resected.&#xD;
&#xD;
          3. Receipt of greater than 2 lines of systemic treatment between Vigil manufacture and&#xD;
             screening for this protocol.&#xD;
&#xD;
          4. Live vaccine used for the prevention of infectious disease administered &lt; 30 days&#xD;
             prior to the start of study therapy.&#xD;
&#xD;
          5. Post-surgery complication that in the opinion of the treating investigator would&#xD;
             interfere with the subject's study participation or make it not in the best interest&#xD;
             of the patient to participate.&#xD;
&#xD;
          6. Brain metastases unless treated with curative intent (gamma knife or surgical&#xD;
             resection) and without evidence of progression for ≥ 2 months.&#xD;
&#xD;
          7. Any documented history of autoimmune disease with exception of Type 1 diabetes on&#xD;
             stable insulin regimen, hypothyroidism on stable dose of replacement thyroid&#xD;
             medication, vitiligo, or asthma not requiring systemic steroids.&#xD;
&#xD;
          8. Known HIV or chronic Hepatitis B or C infection.&#xD;
&#xD;
          9. Known history of allergies or sensitivities to gentamicin.&#xD;
&#xD;
         10. History of or current evidence of any condition (including medical, psychiatric or&#xD;
             substance abuse disorder), therapy, or laboratory abnormality that might confound the&#xD;
             results of the study, interfere with the patient's participation for the full duration&#xD;
             of the study, or is not in the best interest of the patient to participate, in the&#xD;
             opinion of the treating Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Luisa Manning, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gradalis, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Oncology - Pediatrics</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M, Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N, Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan DM, Maples PB, Nemunaitis J. Phase I trial of &quot;bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell&quot; vaccine (FANG) in advanced cancer. Mol Ther. 2012 Mar;20(3):679-86. doi: 10.1038/mt.2011.269. Epub 2011 Dec 20.</citation>
    <PMID>22186789</PMID>
  </reference>
  <reference>
    <citation>Ghisoli M, Barve M, Mennel R, Lenarsky C, Horvath S, Wallraven G, Pappen BO, Whiting S, Rao D, Senzer N, Nemunaitis J. Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma. Mol Ther. 2016 Aug;24(8):1478-83. doi: 10.1038/mt.2016.86. Epub 2016 Apr 25.</citation>
    <PMID>27109631</PMID>
  </reference>
  <reference>
    <citation>Ghisoli M, Barve M, Schneider R, Mennel R, Lenarsky C, Wallraven G, Pappen BO, LaNoue J, Kumar P, Nemunaitis D, Roth A, Nemunaitis J, Whiting S, Senzer N, Fletcher FA, Nemunaitis J. Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma. Mol Ther. 2015 Jun;23(6):1103-1109. doi: 10.1038/mt.2015.43. Epub 2015 Mar 19.</citation>
    <PMID>25917459</PMID>
  </reference>
  <reference>
    <citation>Ghisoli M, Rutledge M, Stephens PJ, Mennel R, Barve M, Manley M, Oliai BR, Murphy KM, Manning L, Gutierrez B, Rangadass P, Walker A, Wang Z, Rao D, Adams N, Wallraven G, Senzer N, Nemunaitis J. Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy. J Pediatr Hematol Oncol. 2017 May;39(4):e183-e186. doi: 10.1097/MPH.0000000000000822.</citation>
    <PMID>28338569</PMID>
  </reference>
  <reference>
    <citation>Oh J, Barve M, Matthews CM, Koon EC, Heffernan TP, Fine B, Grosen E, Bergman MK, Fleming EL, DeMars LR, West L, Spitz DL, Goodman H, Hancock KC, Wallraven G, Kumar P, Bognar E, Manning L, Pappen BO, Adams N, Senzer N, Nemunaitis J. Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. Gynecol Oncol. 2016 Dec;143(3):504-510. doi: 10.1016/j.ygyno.2016.09.018. Epub 2016 Sep 24.</citation>
    <PMID>27678295</PMID>
  </reference>
  <reference>
    <citation>Rocconi RP, Grosen EA, Ghamande SA, Chan JK, Barve MA, Oh J, Tewari D, Morris PC, Stevens EE, Bottsford-Miller JN, Tang M, Aaron P, Stanbery L, Horvath S, Wallraven G, Bognar E, Manning L, Nemunaitis J, Shanahan D, Slomovitz BM, Herzog TJ, Monk BJ, Coleman RL. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Oncol. 2020 Dec;21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7.</citation>
    <PMID>33271095</PMID>
  </reference>
  <reference>
    <citation>Oh J, Barve M, Senzer N, Aaron P, Manning L, Wallraven G, Bognar E, Stanbery L, Horvath S, Manley M, Nemunaitis J, Walter A, Rocconi RP. Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance. Gynecol Oncol Rep. 2020 Sep 17;34:100648. doi: 10.1016/j.gore.2020.100648. eCollection 2020 Nov. Erratum in: Gynecol Oncol Rep. 2021 Mar 01;36:100740.</citation>
    <PMID>33364285</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 13, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

